Agios reported a net income of $1.9 billion for Q1 2021, driven by the sale of its oncology business. The company is focusing on genetically defined diseases, with upcoming regulatory filings for mitapivat and initiation of Phase 3 studies.
Closed the sale of the oncology portfolio to Servier for $1.8 billion upfront.
Initiated repurchase of up to $1.2 billion of outstanding shares.
Advanced mitapivat development with presentations at the EHA 2021 Virtual Congress and planned regulatory submissions.
Focused on expanding genetically defined disease portfolio with new clinical studies.
Agios plans to finalize global regulatory filings for mitapivat, initiate Phase 3 studies in thalassemia, and advance clinical development of PKR and PKM2 activators.
Analyze how earnings announcements historically affect stock price performance